Atherosclerosis clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

    open to eligible people ages 18-85

    The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

    Orange, California and other locations

Last updated: